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Highlights of the review: 
● TG2 has critical and multifaceted roles beyond ECM crosslinking 
● TG2 function depends on its localization and allosterically-regulated conformation  
● TG2 is upregulated in the pathogenesis of a wide variety of chronic diseases 
● Many similarities exist between the roles of TG2 in the scar tissue and tumor 
stroma  
● TG2 facilitates both TGF-β1 storage in the ECM and TGF-β1 activation 
● TG2 is an important cell adhesion and signaling protein at the cell membrane 
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Abstract:  
Tissue transglutaminase (TG2) is upregulated in the pathogenesis of a wide variety of chronic 
diseases. In this review special emphasis will be placed on fundamental mechanisms underlying 
the critical role of TG2 in fibroproliferative disorders. TG2 is best known for its cross-linking 
capacities in the extracellular space but has many critical and multifaceted roles beyond protein 
cross-linking, which are driven by the conformation and specific localization of the molecule.  
As extracellular crosslinker TG2 promotes fibrotic disease through the storage of latent TGF-β1 
in a stiffened extracellular matrix (ECM). As membrane-bound cell adhesion cofactor and 
signaling protein and intracellular crosslinker or G-protein, TG2 promotes fibrotic disease 
through cell survival and profibrotic pathway activation on a signaling, transcriptional and 
translational level. Similarities between the roles that TG2 plays in scar tissue and in the tumor 
stroma suggest that a deeper understanding of key common pathways in disease pathogenesis 
and progression might lead to the identification of novel treatment targets and the development 
of new drugs and diagnostic methods.  
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TG2 - more than an ECM crosslinker 
Tissue transglutaminase (TG2), also named tTG, EC 2.3.2.13, is the most studied 
representative of a structurally and functionally related family of proteins of which nine members 
have been identified in humans [1,2]. TG2 is best known for its catalytic transamidation activity, 
resulting in the Ca2+ dependent post-translational formation of covalent isopeptide bonds 
between glutamine and lysine residues [1]. Beyond its catalytic core, TG2 consists of an N-
terminal β-sandwich and two C-terminal β-barrel domains (Figure 1, left) [3–5]. Far less 
understood are TG2s multiple functions at the cell membrane, in the cytoplasm and in the cell 
nucleus, such as adhesion, migration, growth, proliferation, survival, apoptosis, differentiation 
and phenotype modulation [6,7]. TG2 is an integrin and syndecan-binding adhesion co-receptor 
for fibronectin (Fn). Approximately 5–40% of β1 integrins are in complex with TG2 and almost all 
cell-membrane bound TG2 forms 1:1 complexes with integrins [8,9], which suggests a 
prominent role for TG2 at the cell membrane. While the focus is often on its crosslinking 
capacities in the extracellular space, TG2 is also active through non-enzymatic protein–protein 
interactions in both the extra- and intracellular space as further highlighted below. The reader is 
also referred to the following comprehensive review [10]. 
 
TG2 is upregulated in the pathogenesis of a wide variety of chronic diseases 
In most cases, the pathophysiological significance of TG2-induced modifications remains 
unclear. However, it is well documented that TG2 is involved in the pathogenesis of a wide 
variety of diseases, most notably neoplastic and fibroproliferative, including most malignant 
cancers and pulmonary, kidney and cardiac fibrosis [11–14]. TG2 expression is highly 
correlated with cancer cell survival, malignancy, metastasis and treatment resistance [13,15]. 
TG2 morphologically and functionally ‘shapes’ the tumor and scar tissue stroma through ECM 
cross-linking and binding of TGF-β1 to the ECM, thus priming TGF-β1, one of the most effective 
profibrotic stimuli, for release and activation [16,17]. Also, through its cell attachment and 
signaling mediator functions and its intracellular signaling and crosslinking functions, TG2 can 
promote tumor cell survival and the development of fibrotic (scar) cell phenotypes [7,8,18–23]. 
Major attempts are thus underway to develop potent TG2 inhibitors. 
 
Environmental sensing through major conformational TG2 changes 
The biochemical functions of TG2 largely depend on its molecular conformation (Figure 1). 
Various environmental factors cause allosteric conformational changes and include 
extracellular, intracellular and intranuclear Ca2+ concentrations, GDP and GTP concentrations 
and MMP-mediated release of membrane bound TG2 into the ECM [7,9]. When bound to GTP 
or GDP, TG2 adopts a closed conformation with the two C-terminal β-barrel domains folded in 
and blocking substrate access to the catalytic site. However, with excess Ca2+ levels, TG2s 
affinity for GDP and GTP is reduced leading to a very large change in molecular shape 
presenting an open molecular conformation with an accessible active catalytic cross-linking site 
(Figure 1b) [3,24]. Low Ca2+ and high GDP/GTP concentrations in the cytoplasm cause TG2 to 
adopt a predominantly closed conformation inside the cell [25]. The conformation that TG2 
adopts at the cell membrane is largely unknown. No structure has yet been solved of TG2 
complexed to any binding partner even though Fn can bind to the open and closed 
conformations of TG2 [5]. Closed state cytosolic TG2 can bind to heparan sulfate epitopes on 
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exosome membrane associated Syndecan-4 molecules which have a high binding affinity for 
the closed conformation of TG2. Syndecan-4-dependent translocation of TG2 from the 
cytoplasm to the extracellular space takes place by fusion of exosomes with the outer cell 
membrane [9,26–28]. This mechanism was identified in fibrotic kidney disease by Furini et al. 
[27]. Syndecan-4-associated TG2 delivered to the cell surface can interact with integrins and 
fibronectin to form membrane associated protein complexes exerting cell adhesion/receptor 
protein functions (Figure 2, 3) [7,29]. MMP2/9 activity can lead to Syndecan-TG2 shedding from 
the cell surface (Figure 3)[9]. Finally, TG2 predominantly adopts an open conformation in the 
extracellular space due to high Ca2+ and low GDP/GTP concentrations [24]. Formation of two 
disulfide bonds between cysteine residues under oxidizing conditions at the catalytic site 
renders TG2 catalytically inactive in its open conformation [30]. Active oxygen reduction 
mechanisms in the ECM therefore promote the catalytic ECM cross-linking activity of TG2 in the 
extracellular space [31]. Mechanical forces within the physiological range for cells have been 
shown to induce allosteric conformational and functional changes in proteins [32]. Also, TG2 is 
concentrated at focal adhesion sites [8,18] and the integrin and Fn-binding sites are located at 
opposite sides of the TG2 molecule with the catalytically active site and hinge region in between 
(Figure 1) [4]. It is therefore likely that cells that generate mechanical forces and pull at 
adhesion sites that are physically connected to the extracellular matrix can induce TG2 
‘opening’ and catalyze disulfide bond reduction, thus inducing and stabilizing an open 
catalytically active conformation of TG2 [3,4]. 
Extra- and intracellular: Transamidation and cross-linking functions of TG2 / TGF-β1 
storage in the ECM 
The catalytic activity of TG2 can affect protein conformation by generating intramolecular cross-
links and can catalyze the formation of covalently linked dimers, oligomers, and polymers [6]. 
The transamidation activity of TG2 results in protease-resistant inter- or intramolecular 
isopeptide bonds which effectively cross-link ECM fibrils, stiffening the ECM and protecting the 
ECM from proteolytic degradation [24]. A matrix reservoir of inactive TGF-β1 is formed via TG2-
mediated cross-linking of latent TGF-β1 binding protein (LTBP-1) to the ECM (Figure 2, 3) 
[33,34]. ECM-bound TGF-β1 can be activated via mechanical release (Figure 3), which is 
especially effective when the LTBP-1 is bound to a stiff, deformation resistant ECM that 
counters cell-applied forces [17,33,35,36]. As such, TGF-β1 activation is thought to be facilitated 
by TG2 since TG2 cross-links LTBP to the ECM and can turn a compliant matrix into a stiffer 
matrix via cross-linking of various ECM components [37]. ECM prestress sensitizes latent TGF-
β1 for activation [36], which might explain increased TGF-β1 release from stiffened fibrotic 
tissues. Since increased and dysregulated expression, deposition and cross-linking of ECM 
cause loss of vital organ function in fibrosis, TG2 and TGF-β1 are explored as targets for the 
treatment of fibrotic diseases. 
 
 
Cell membrane: TG2 regulates cell adhesion and ligand affinity 
TG2 binds to the fibronectin type I modules FnI7–9 of the collagen/gelatin binding site on the Fn 
molecule and interacts with cell membrane β1, β3 and β5 integrins [8,38–40] and/or syndecan-4 
(Figure 3) [9,28,29]. Syndecan-4 and integrin signaling is coordinated via direct complex 
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formation of Fn-TG2, β-integrins and syndecan-4, indirect integrin cytoplasmic tail activation via 
Syndecan-4 activated PKCɑ or downstream convergence of integrin and syndecan signaling at 
p190RhoGAP (Figure 3) [29,41]. TG2-Fn-complexes offer cells an alternative binding site on Fn 
in addition to the classical integrin-Fn binding sites (e.g. RGD loop, synergy site) and facilitate 
RGD independent cell adhesion [28,29,42,43].  
By promoting cell adhesion to Fn via cell surface integrins and syndecan-4, TG2 likely 
stimulates Fn fibril assembly through cell contraction-mediated Fn stretching and unmasking of 
Fn self-assembly sites [38,44]. Indirectly, integrin clustering and binding of TG2 at focal 
adhesions might concentrate TG2 catalyzed cross-linking of the dense Fn matrix at these sites 
as suggested by Zemskov et al. [18]. 
Proteolytic degradation of surface TG2 can shift cell-ECM recognition: cells cannot bind to 
collagen, if TG2 is bound to certain collagen-binding integrins, such as integrin α1β1, likely due 
to steric hindrance [18]. MT1-MMP and/or MMP-2 degrade integrin-associated cell surface TG2 
and restore α1β1 integrin-collagen interactions, while at the same time suppressing cell 
adhesion and migration on fibronectin. This shift in cell-ECM recognition via dynamic regulation 
of surface TG2 can affect adhesion and migration of cells on various ECM ligands [7,18].  
The importance of TG2 for cell adhesion is underlined by the discovery that TG2 was 1 out of 
only 10 proteins that consistently appeared in seven integrin adhesome datasets analyzed by 
Horton et al. [45].  
 
Cell membrane: TG2 as signaling protein  
Almost all cell membrane-associated TG2 is bound to integrins [8], where TG2 dimers facilitate 
integrin clustering formation (Figure 3)[7,19]. Further ECM components (e.g. Fn) and cell 
membrane protein receptors that bind next to fibronectin’s RGD-specific integrin binding site 
(e.g. Syndecan-4, PDGF, VEGF, FGF and EGF receptors) can be engaged by these TG2-
integrin complexes to execute various cell adhesion (described above) and signaling functions 
(Figure 3) [7,9,21,29]. TG2-integrin clusters, TG2-Fn-integrin and TG2-Fn-integrin-syndecan-4 
complexes are known to activate well reviewed integrin signaling cascades, resulting in RhoA-
ROCK activation, actin filamentation and downstream release and nuclear translocation of 
MRTF-A and YAP/TAZ (Figure 3) [7,8,19,46,47]. Nuclear MRTF-A and YAP/TAZ both act as 
transcription cofactors that promote expression of profibrotic genes, including ɑSMA, Tenascin-
C and CTGF,  which can influence the tumor stroma and cancer development and promote 
fibrotic disease [17,48,49].  
 
Inside the cell: Enzymatic and non-enzymatic TG2 activity 
With low Ca2+ and high GDP/GTP concentrations in the cytoplasm, TG2 binds to and hydrolyzes 
GTP, assumes a closed conformation and acts as a G protein. For example, TG2 binds to c-Src 
and PI3-kinase, facilitating c-Src-dependent phosphorylation of PI3-kinase which promotes cell 
survival [22]. Due to fluctuations in Ca2+ levels, cytoplasmic open conformation cross-linking 
activity of TG2 can also be observed with various specific and unspecific target proteins. For 
example, TG2 drives the constitutive activation of NF-κB through its cross-linking activity, which 
leads to increased TGF-β1 expression (e.g. fibrotic diseases, cancer stroma), promotion of 
epithelial-mesenchymal transformation (increasing tumor malignancy) and cell survival [23,49]. 
Similarly, RhoA cross-linking and activation leads to increased stress fiber formation [50] and 
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certain translation regulatory proteins like YB-1 can be crosslinked in a state that drives 
increased ɑSMA protein translation [20]. TG2 also regulates mitochondrial function and can 
initiate mitochondrial-driven apoptosis by crosslinking mitochondrial proteins in its open, 
catalytically active state [24,51]. At the same time, TG2 cross-linking stabilizes the structure of 
dying cells, prevents leakage of proteolytic enzymes and protects the environment of the cell 
from further damage [52]. Last, high TG2 levels increase autophagy of the tumor suppressor 
p53, which can help tumor cells escape apoptosis [53]. 
Nuclear TG2 has been shown to regulate gene expression via post-translational modification of 
transcriptional factors and related proteins, including Sp1, hypoxia inducible factor (HIF) 1 and 
histones [54]. The G-protein function of cytosolic TG2 typically enhances cell survival [22], 
whereas the transamidation activity of TG2 can lead to cell death or survival or even fibrotic 
changes [20,23,49–51,55], depending on the target protein(s). Nuclear localization of TG2 is 
generally protective against cell death [56,57].  
 
TG2 as major player in the development and maintenance of fibroproliferative diseases 
Fibroproliferative disorders cause approximately 45% of the mortality in the developed world 
and appear in a wide spectrum from systemic to organ-specific fibrotic diseases. Besides 
increased mechanical tissue tension and the presence of certain ECM components like cellular 
fibronectin’s ED-A domain, TGF-β1 is one of the most effective profibrotic stimuli that drive the 
transformation of fibroblasts into myofibroblasts [17]. Myofibroblasts are the key players within 
fibroproliferative disorders [17,58]. They incorporate an excess of collagen and other fibrous 
proteins into the ECM while expressing strong contractile alpha smooth muscle actin (αSMA) 
positive stress fibers which contract the fibrotic matrix into a stiff, dysfunctional scar 
[17,33,48,59]. Interestingly, TG2 and TGF-β1 reinforce each other in the progressive fibrotic and 
tumor stroma microenvironment [49]. As described in previous sections, TG2 facilitates the 
activation of TGF-β1 in the ECM [16], the activation of profibrotic signaling cascades 
downstream from TG2-β-integrin-containing membrane signaling complexes [7] and the 
translation of αSMA [20]. TGF-β1 on the other hand promotes TG2 transcription [60,61] leading 
to self-amplification of TG2 and TGF-β1 in fibrotic tissues and explaining why both are 
upregulated in fibroproliferative disorders. The fact that TG2 knockout mice were protected 
against fibrosis [62,63] and that TG2 inhibition in mouse models of fibrosis significantly reduced 
the fibrotic phenotype [11,12,64] further underlines the critical role that TG2 plays in the 
pathogenesis and maintenance of fibrosis [65]. The relative contributions of catalytic and non-
catalytic TG2 functions to healthy and diseased microenvironments still remain unknown. 
Inhibition of TG2s catalytic function can reduce cardiac fibrosis in vivo [11,64,66]. Wang et al. 
and Shinde et al. suggested further reduction of fibrosis via non-catalytic TG2-mediated 
mechanisms: reduced externalization of TG2 as a result of decreased interaction of intracellular 
TG2 with exosome membrane associated syndecan-4, decreased TGF-β1-induced 
myofibroblast formation and reduced activation of fibrosis-associated genes [11,64].  
 
Outlook: TG2 as common denominator in fibroproliferative and neoplastic diseases 
The consensus in cancer research seems to mirror our descriptions of the profibrotic functions 
of TG2 outlined above. Extracellular TG2 in its open enzymatically active conformation 
promotes cancer cell malignancy through crosslinking of the tumor stroma [49,55]. Intracellular 
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closed conformation TG2 promotes cancer cell survival and malignancy through survival 
pathway and EMT activation [22,49]. Stabilizing the open state of TG2 inside the cell promotes 
cell death and inhibits the malignant phenotype of cancer cells, thus representing a promising 
new avenue in the treatment of cancer [24,25]. Similarities between scar tissue and tumor 
stroma [67–69] suggest that the identification of key common pathways involved in the disease 
pathogenesis and progression might lead to the identification of novel treatment targets and the 
development of new drugs and diagnostic methods. 
Beyond its role as ECM crosslinker, much future research is needed to understand the many 
roles of TG2, including cell adhesion stabilization and its nuclear functions. Also, translational 
research is required as just a few TG2 inhibitors are in clinical trials and none is available for 
clinical use [55].  
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Figures + legends   
All figures are to be printed in color! 
 
 
Figure 1:   
Functional domains, binding sites and structure of tissue transglutaminase (TG2).  
Beyond its catalytic core (140 - 454), TG2 consists of an N-terminal β-sandwich motif (1 - 139) 
and two C-terminal β-barrel domains(1: 469-591; 2: 592-687) [3–5]. The most relevant 
functional binding sites will be described briefly.  
A) Recent studies identified residues K30, R116 and H134 on the N-terminal β-sandwich 
(yellow) as critical binding partners for the 42 kDa gelatin binding domain of Fn [5]. 
According to Belkin et al. TG2-integrin binding is disrupted upon deletion of C-terminal β-
barrel 2 (blue), which indicates that integrin binding sites reside on that domain [4]. The 
catalytic core region (magenta) contains the active cross-linking site with the catalytic 
triad residues (C277, H335, D358). GTP (nucleotide) binding takes place on the catalytic 
core (K173) and β-barrel 1 (green) (R476k R478, V479, M483,R580, Y583) [70]. Heparin 
binding sites were identified on the catalytic core and β-barrel 2 [71]. (*) Wang et al. 
identified an alternative heparin binding site [9]. Ca2+-binding to five of six Ca2+ binding 
sites on the catalytic core fosters allosteric catalytic site activation [72]. For information 
regarding further binding sites (α1β-adrenergic receptor, PLCδ1, nuclear export 
signaling peptide) the reader is referred to the following references [70,71]. 
B) X-ray crystallography demonstrated that enzymatic cross-linking activity of TG2 is only 
possible in the Ca2+-induced open-state conformation (PDB: 2Q3Z, [3]) with exposed 
catalytic triad residues. Nucleotide binding induces the closed-state conformation (PBD: 
1KV3) with catalytic triad residues blocked by β-barrels 1 and 2 [73]. However, since 
TG2 has many non-enzymatic functions, “conformational state” and “activity” must be 
carefully distinguished [24]. 
Figures are adapted and modified with permission from A [70] and B [24]. 
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Figure 2:  
TG2 functions depend on its localization, as well as its allosterically-regulated 
conformation as upregulated in many diseases.  
Resident fibroblasts deposit and remodel the ECM in healthy tissues (top and middle left) [44], 
whereas αSMA expressing contractile myofibroblasts are the key players in fibrotic disease (top 
and middle right). Myofibroblast-dominated tissues are characterized by increased ECM fiber 
density and cross-linking. TG2 and TGF-β1 are both upregulated in fibrotic tissues. The open 
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conformation of TG2 cross-links ECM fibrils ① [1], and binds latent TGF-β1 via LTBP-1 to the 
ECM ② [1,34,74].  TG2 interacts in closed or unknown conformation with cell membrane 
proteins ③, resulting in downstream signaling effects [9,29,41]. Cytosolic ④ and nuclear ⑤ 
TG2 activate intracellular signaling pathways and downstream gene expression through 
enzymatic (open state TG2) and non-enzymatic (closed state TG2) mechanisms. 
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Figure 3:  
Key pro-fibrotic roles of TG2 at the cell membrane and in the ECM. 
The molecular sketches do not represent molecular dimensions nor potential conformational 
states. Unconventional cellular release and reuptake of TG2 are not depicted in this scheme. 
Figures are adapted and modified with permission from Belkin et al. [7] and Robertson et al. 
[75].  
 
Membrane associated functions of TG2 (lower left section of figure): 
TG2-integrin clusters, TG2-FN-Integrin and TG2-FN-integrin-syndecan-4 complexes are known 
to activate intracellular Src-FAK and inhibit p190RhoGAP through Src, with both pathways 
leading to RhoA-ROCK activation [7,8,19,29,41]. RhoA/ROCK pathway activation induces the 
assembly of cytoplasmic monomeric G-actin into F-actin fibers and the formation of stress 
fibers. Changes in actin dynamics are monitored by myocardin-related transcription factor A 
(MRTF-A), which binds to cytoplasmic G-actin, but dissociates from F-actin. Upon actin fiber 
assembly MRTF-A thus uncouples from G-actin and the released MRTF-A enters the nucleus. 
Alternatively, Rho-signaling and cytoskeletal stress drive the downregulation of YAP/TAZ 
phosphorylation and the subsequent nuclear translocation and activation of YAP/TAZ. Nuclear 
MRTF-A and YAP/TAZ both act as transcription cofactors that promote profibrotic gene 
expression [46,47]. RGD independent cell adhesion to Fn depends on Fn-TG2-syndecan-4 
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interaction and is mediated via cytoplasmic α5β1 integrin and syndecan-2 activation by 
Syndecan-4 activated PKCɑ [29]. Membrane-associated TG2 interacts with growth factor 
receptors (such as for PDGF, VEGF, FGF and EGF) and stimulates cell survival signaling 
pathways (e.g. FAK, Src, Akt, etc.) by promoting GF-receptor binding and activation [7,21]. 
 
Storage of latent TGF-β1 in the ECM and mechanoactivation of TGF-β1 (right section of figure): 
TGF-β1 is secreted by cells in complex with its latency associated propeptide (LAP), which 
associates with latent TGF-β1 binding protein (LTBP-1) [76]. LTBP-1 facilitates secretion of 
TGF-β1 [77] and TG2 cross-links LTBP-1 to Fn and fibrillin ECM fibers  [16,34]. As such, a 
matrix reservoir of inactive TGF-β1 is formed which is bound to the LTBP-1 and ECM and 
therefore unable to bind with its high affinity cell membrane receptor to activate the downstream 
SMAD-mediated signaling cascade [34,74]. Latent TGF-β1 can be activated through its release 
from the ECM-bound TGFβ-LAP-LTBP-1 complex by proteolysis  or integrin mediated cellular 
contraction  [33–35]. The N- and C-terminal matrix binding sequences of LTBP-1 [78] and 
integrin binding RGD sequence of LAP [79] are critical for the activation of TGF-β1. Cell 
membrane associated integrins bind to the RGD sequence on LAP  and can expose the ECM 
bound LTBP-1 to cellular contractile forces. This is especially effective when the LTBP-1 is 
bound to a stiff, deformation resistant ECM that counters cell-applied forces [17,33,35,36]. As 
such, TGF-β1 activation is thought to be facilitated by TG2 since TG2 cross-links LTBP to the 
ECM and can stiffen a compliant matrix via ECM cross-linking [37]. For a detailed review on 
TGF-β-LTBP interactions we refer the reader to a recent comprehensive review published by 
Rifkin et al. [74].  
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